Neuronetics Inc. stocks have been trading up by 22.58 percent amid bullish sentiment on its expanding depression-treatment technology adoption.
Click Here for a Millionaire's POV on Trading STIM
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways Traders Are Watching
- BTIG launched coverage on Neuronetics with a Buy rating and $5 target, pointing to STIM’s vertically integrated interventional psychiatry model and 93 Greenbrook-operated treatment centers.
- A new National Center of Excellence in Rockville, MD showcases NeuroStar TMS, SPRAVATO, and pilots future psychedelic-class therapies, reinforcing the STIM growth story.
- A fresh understanding with major holder Jorey Chernett and public backing from Madryn Asset Management signals aligned, supportive long-term capital behind Neuronetics.
- Leadership moves, including new CFO Nir Naor and an elevated Greenbrook GM, aim to tighten financial discipline and clinic execution across the STIM platform.
- Q2 2026 results on 2026/08/11 are the next key checkpoint for traders tracking Neuronetics and its Greenbrook network performance.
Live Update At 09:17:44 EDT: On Tuesday, August 11, 2026 Neuronetics Inc. stock [NASDAQ: STIM] is trending up by 22.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
STIM has been grinding higher on the chart. From 2026/07/17 to 2026/08/10, Neuronetics climbed from a $1.62 close to $2.17, with a push as high as $2.43 along the way. That is a strong multi-week trend, especially for a beaten-down small-cap medical name.
Intraday action shows what active traders love. Pre-market prints above $2.90, followed by fast swings back toward the mid-$2.50s, signal real liquidity and emotions around STIM. Those sharp wicks tell you momentum traders are already circling the name.
Fundamentally, Neuronetics is still a turnaround. Revenue over the last year was about $149.2M, growing solidly, and gross margin is a healthy 48%. But profit margins are deeply negative, and STIM is burning cash, with Q1 2026 free cash flow at roughly -$9.6M and net income at about -$10.8M. Leverage is high, with total debt stacked against a thin equity base and a price-to-book that reflects this risk.
More Breaking News
- NCRA Stock Jumps As Nocera Grabs Qmax AI Memory Stake
- OGI Stock Builds Momentum As Sanity Group Delivers In Germany
- Sea Limited Stock Firms As Traders Eye Q2 Earnings
- Rubrik Stock Climbs As CSA Names It AI Security Vanguard
For traders, that mix — strong top-line growth, heavy losses, and high debt — usually means volatility. When the story is “fix the model and scale,” each earnings call and clinic update can swing STIM hard in either direction.
Why Traders Are Watching STIM Right Now
What changed the tone around Neuronetics is the story, not just the numbers. BTIG stepped in with Buy coverage and a $5 price target, almost a “re-rate me” sign taped to STIM. The firm is betting the 2024 Greenbrook TMS deal, which gave Neuronetics 93 company-operated clinics, turned the business into a true vertical platform: it owns the NeuroStar TMS device, and it controls a large portion of the patient delivery system.
For traders, that matters. Vertical models, when they work, can drive better margins over time and give companies more pricing and data leverage. If STIM can push more NeuroStar usage through its Greenbrook network and layer in additional treatments, the revenue base starts to look more durable and scalable.
The new National Center of Excellence in Rockville is the physical proof of that plan. It is positioned as a high-volume flagship for NeuroStar and SPRAVATO, and a test bed for future interventional and psychedelic-class therapies. A single flagship hub like this can punch above its weight in branding and learning curves, feeding best practices back into the broader STIM footprint.
Backing this, major shareholder Jorey Chernett and top holder Madryn Asset Management have effectively said they are aligned with management and comfortable with the capital position. For STIM traders who worry about surprise activism, that lowers the odds of messy boardroom drama near term and lets the execution story stay front and center.
Management changes add another layer. Bringing in former Axogen CFO Nir Naor, while also promoting Cory Anderson to run Greenbrook as EVP & GM, signals that Neuronetics is trying to tighten the screws on both finance and operations. Yes, the departure of the chief legal officer introduces some transition risk, but the overall message is: “We’re serious about scaling this thing correctly.”
Conclusion
STIM now sits at an interesting crossroads. The chart trend is up, volume is alive, and the narrative around Neuronetics has shifted from “can they survive” to “can they execute on this vertical interventional psychiatry platform.” BTIG’s Buy rating and $5 target give traders a concrete reference point, and the combination of Greenbrook clinics plus proprietary NeuroStar TMS technology is a cleaner story than it was a year ago.
But traders still have to respect the risks. Neuronetics is unprofitable, levered, and burning cash. The business needs operating leverage from those 93+ clinics, and it needs sites like the Rockville Center of Excellence to drive real revenue, not just headlines. If that scaling stalls, STIM can unwind quickly — especially with a stretched price-to-book and negative returns on equity and assets.
The next catalyst is clear: Q2 2026 numbers and the conference call on 2026/08/11. That is where management has to show how Greenbrook integration is tracking, how clinic-level economics look, and how soon STIM expects cash burn to narrow. Active traders should study the chart, map key levels around recent highs and the $5 BTIG target, and be ready for volatility around that print. That also means being okay with standing aside if the setup isn’t clean — as Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.”
As Tim Sykes likes to remind traders, “Patterns repeat, but only if you’re prepared.” STIM is shaping up as a classic small-cap momentum pattern built on a real fundamental shift — but the only way to trade it smart is by staying disciplined, cutting losses fast, and letting the price action confirm the story, not the other way around.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.